Annexon (NASDAQ:ANNX) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Annexon (NASDAQ:ANNX) issued its quarterly earnings data on Monday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05), Zacks reports.

Annexon Price Performance

Annexon stock opened at $2.39 on Tuesday. The firm has a market cap of $254.76 million, a price-to-earnings ratio of -2.28 and a beta of 1.07. Annexon has a fifty-two week low of $2.39 and a fifty-two week high of $8.40. The firm has a fifty day moving average price of $3.96 and a two-hundred day moving average price of $5.42.

Analyst Upgrades and Downgrades

ANNX has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Annexon in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.